Difference between revisions of "SMARCB1"
Jump to navigation
Jump to search
(tweak) |
(tweak) |
||
| Line 12: | Line 12: | ||
| Pattern = | | Pattern = | ||
| Positive = any healthy tissue | | Positive = any healthy tissue | ||
| Negative = [[AT/RT]], [[ | | Negative = [[AT/RT]], [[renal rhabdoid tumour]], [[extrarenal malignant rhabdoid tumour]], [[epithelioid sarcoma]] | ||
| Other = | | Other = | ||
}} | }} | ||
'''SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1''', commonly abbreviated '''SMARCB1''' (or '''INI1''' or '''BAF47'''), is a diagnostic [[immunostain]], because nuclear staining is lost in some specific types of cancer shown below. | '''SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1''', commonly abbreviated '''SMARCB1''' (or '''INI1''' or '''BAF47'''), is a diagnostic [[immunostain]], because nuclear staining is lost in some specific types of cancer shown below. | ||
==Negative== | ==Negative== | ||
* [[Epithelioid sarcoma]].<ref>Hornick, Jason (2009). "Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma". American Journal of Surgical Pathology.</ref> | |||
* [[Epithelioid sarcoma]] <ref>Hornick, Jason (2009). "Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma". American Journal of Surgical Pathology.</ref> | * [[Extrarenal malignant rhabdoid tumour]].<ref>Jackson EM, Sievert AJ, Gai X et al. (March 2009). "Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors". Clin. Cancer Res. 15 (6): 1923–30.</ref> | ||
* [[Extrarenal malignant rhabdoid tumour]] <ref>Jackson EM, Sievert AJ, Gai X et al. (March 2009). "Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors". Clin. Cancer Res. 15 (6): 1923–30.</ref> | * [[Renal rhabdoid tumour]]. | ||
* [[Renal rhabdoid tumour]] | * SMARCB1 (INI-1)-deficient carcinomas of the sinonasal tract.<ref name=pmid25007146>{{Cite journal | last1 = Bishop | first1 = JA. | last2 = Antonescu | first2 = CR. | last3 = Westra | first3 = WH. | title = SMARCB1 (INI-1)-deficient carcinomas of the sinonasal tract. | journal = Am J Surg Pathol | volume = 38 | issue = 9 | pages = 1282-9 | month = Sep | year = 2014 | doi = 10.1097/PAS.0000000000000285 | PMID = 25007146 }}</ref> | ||
* SMARCB1 (INI-1)-deficient carcinomas of the sinonasal tract <ref name=pmid25007146>{{Cite journal | last1 = Bishop | first1 = JA. | last2 = Antonescu | first2 = CR. | last3 = Westra | first3 = WH. | title = SMARCB1 (INI-1)-deficient carcinomas of the sinonasal tract. | journal = Am J Surg Pathol | volume = 38 | issue = 9 | pages = 1282-9 | month = Sep | year = 2014 | doi = 10.1097/PAS.0000000000000285 | PMID = 25007146 }}</ref> | * [[Atypical teratoid/rhabdoid tumour]].<ref>{{Cite journal | last1 = Hasselblatt | first1 = M. | last2 = Isken | first2 = S. | last3 = Linge | first3 = A. | last4 = Eikmeier | first4 = K. | last5 = Jeibmann | first5 = A. | last6 = Oyen | first6 = F. | last7 = Nagel | first7 = I. | last8 = Richter | first8 = J. | last9 = Bartelheim | first9 = K. | title = High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors. | journal = Genes Chromosomes Cancer | volume = 52 | issue = 2 | pages = 185-90 | month = Feb | year = 2013 | doi = 10.1002/gcc.22018 | PMID = 23074045 }}</ref> | ||
* [[Atypical teratoid/rhabdoid tumour]] <ref>{{Cite journal | last1 = Hasselblatt | first1 = M. | last2 = Isken | first2 = S. | last3 = Linge | first3 = A. | last4 = Eikmeier | first4 = K. | last5 = Jeibmann | first5 = A. | last6 = Oyen | first6 = F. | last7 = Nagel | first7 = I. | last8 = Richter | first8 = J. | last9 = Bartelheim | first9 = K. | title = High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors. | journal = Genes Chromosomes Cancer | volume = 52 | issue = 2 | pages = 185-90 | month = Feb | year = 2013 | doi = 10.1002/gcc.22018 | PMID = 23074045 }}</ref> | |||
==See also== | ==See also== | ||
Revision as of 02:38, 22 September 2015
| SMARCB1 | |
|---|---|
| Immunostain in short | |
 INI1-ve in AT/RT. | |
| Abbreviation | SMARCB1, BAF47 |
| Positive | any healthy tissue |
| Negative | AT/RT, renal rhabdoid tumour, extrarenal malignant rhabdoid tumour, epithelioid sarcoma |
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1, commonly abbreviated SMARCB1 (or INI1 or BAF47), is a diagnostic immunostain, because nuclear staining is lost in some specific types of cancer shown below.
Negative
- Epithelioid sarcoma.[1]
- Extrarenal malignant rhabdoid tumour.[2]
- Renal rhabdoid tumour.
- SMARCB1 (INI-1)-deficient carcinomas of the sinonasal tract.[3]
- Atypical teratoid/rhabdoid tumour.[4]
See also
References
- ↑ Hornick, Jason (2009). "Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma". American Journal of Surgical Pathology.
- ↑ Jackson EM, Sievert AJ, Gai X et al. (March 2009). "Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors". Clin. Cancer Res. 15 (6): 1923–30.
- ↑ Bishop, JA.; Antonescu, CR.; Westra, WH. (Sep 2014). "SMARCB1 (INI-1)-deficient carcinomas of the sinonasal tract.". Am J Surg Pathol 38 (9): 1282-9. doi:10.1097/PAS.0000000000000285. PMID 25007146.
- ↑ Hasselblatt, M.; Isken, S.; Linge, A.; Eikmeier, K.; Jeibmann, A.; Oyen, F.; Nagel, I.; Richter, J. et al. (Feb 2013). "High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors.". Genes Chromosomes Cancer 52 (2): 185-90. doi:10.1002/gcc.22018. PMID 23074045.